<scp>CAR‐T</scp> cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status-Reference-Cited by-同舟云学术

CAR‐T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status

Published:2022-05-05 Issue:7 Volume:97 Page:933-941
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Du Juan¹^ORCID,Wei Runhong²,Jiang Songfu³,Jiang Hua¹,Li Lu¹,Qiang Wanting¹,He Haiyan¹,Shi Lin²,Ma Qiuling²,Yu Kang³,Zhang Xiaoyuan³,Ding Hanyi³,Sun Xuedong⁴,Xiang Fang⁴,Zhu Lin⁴,Cheng Zhi²^ORCID,Fu Weijun¹

Affiliation:

1. Department of Hematology Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University Shanghai China

2. Department of Hematology Henan Province Hospital of Traditional Chinese Medicine (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine), Institute of Hematology, Henan University of Traditional Chinese Medicine Zhengzhou China

3. Department of Hematology The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Zhejiang China

4. HRAIN Biotechnology Co., Ltd. Shanghai China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26583

Reference33 articles.

1. Newly diagnosed myeloma in 2020;Moreau P;Am Soc Clin Oncol Educ Book,2020